^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug Class: | DHODH inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Introducing a novel DHODH inhibitor with superior in vivo activity as monotherapy or in novel combination regimen with immunotherapy for hematological malignancies
Published date:
06/15/2022
Excerpt:
We sought to develop a DHODH inhibitor that had superior properties to those reported for AML therapy....Cmpd 41 also demonstrated superior in vivo anti-leukemic activity in multiple AML xenograft models as monotherapy and demonstrated synergy with a hypomethylating agent, decitabine in TP53 mutated AML....In summary, we introduce a best in class DHODH inhibitor with a data-driven combination strategy for both AML and MM.
DOI:
10.1158/1538-7445.AM2022-1060
